؉ channels (K ATP channels) are composed of pore-forming subunits Kir6.x and sulfonylurea receptors (SURs). Cyanoguanidines such as pinacidil and P1075 bind to SUR and enhance MgATP binding to and hydrolysis by SUR, thereby opening K ATP channels. In the vasculature, openers of K ATP channels produce vasorelaxation. Some novel cyanoguanidines, however, selectively reverse opener-induced vasorelaxation, suggesting that they might be K ATP channel blockers. Here we have analyzed the interaction of the enantiomers of a racemic cyanoguanidine blocker, PNU-94750, with Kir6.2/SUR channels. In patch clamp experiments, the R-enantiomer (PNU-96293) inhibited Kir6.2/SUR2 channels (IC 50 ϳ50 nM in the whole cell configuration), whereas the S-enantiomer (PNU-96179) was a weak opener. Radioligand binding studies showed that the R-enantiomer was more potent and that it was negatively allosterically coupled to MgATP binding, whereas the S-enantiomer was weaker and positively coupled. Binding experiments also suggested that both enantiomers bound to the P1075 site of SUR. This is the first report to show that the enantiomers of a K ATP channel modulator affect channel activity and coupling to MgATP binding in opposite directions and that these opposite effects are apparently mediated by binding to the same (opener) site of SUR.
ATP-dependent K
ϩ channels (K ATP channels) 1 are gated by the intracellular ATP/ADP ratio with ATP inducing channel closure and MgADP channel opening. Functionally, these channels link membrane potential and excitability to the metabolic state of the cell (1, 2) . Pharmacologically, K ATP channels are closed by the hypoglycemic sulfonylureas such as glibenclamide and their benzoic acid analogs, the glinides; these drugs are used in the treatment of diabetes type 2. K ATP channels are activated by the K ϩ channel openers, a chemically heterogeneous group of compounds including the cyanoguanidines like pinacidil and P1075 and the benzopyrans such as levcromakalim; these compounds relax smooth muscle and induce hypotension (2) (3) (4) (5) . K ATP channels are heteromeric complexes composed of poreforming inwardly rectifying K ϩ channels (Kir6.x) and sulfonylurea receptors (SURs) (6, 7) (for reviews, see Refs. 8 -10) . Kir6.x is encoded by either one of two genes giving rise to two subtypes, Kir6.1 and -6.2, with the latter being present in most K ATP channels. ATP binding to Kir6.2 induces channel closure, thus accounting for the inhibitory action of the nucleotide (11) . SUR is a member of the ATP-binding cassette protein superfamily (7, 12) . It carries binding sites for nucleotides, the nucleotide binding folds (13) , and for the sulfonylureas and the openers (12, 14, 15) . SUR also is encoded by either one of two genes. SUR1, expressed in the pancreatic ␤-cell and predominantly in neurons, exhibits high affinity for the sulfonylureas and low affinity for the openers. SUR2 is expressed in the various muscle types and shows high affinity for the openers but lower affinity for the sulfonylureas (14, 15) (for reviews, see Refs. 5 and 16) . Alternative splicing of the SUR2 mRNA leads to two isoforms, SUR2A and SUR2B, which differ only in the last carboxyl-terminal exon. SUR2A is expressed in skeletal and heart muscle; SUR2B is expressed in smooth muscle (17, 18) .
The nucleotides not only gate the channel, they also profoundly affect the potency and efficacy of the synthetic K ATP channel modulators by allosteric interactions. First, there is a positive allosteric interaction between nucleotide and opener binding, enabling SUR to bind openers with high affinity (14 -16, 19, 20) . Conversely, openers enhance the ATPase activity of SUR2A, thereby promoting channel activation (21) . Second, there is a negative allosteric interaction between nucleotide and sulfonylurea binding (22, 23) . Third, there is a negative allosteric coupling between opener and sulfonylurea binding, generally leading to mutually exclusive binding of the two ligands to SUR (14, 15, 19, 24) .
In varying the cyanoguanidine structure, Khan and colleagues (25) discovered that introduction of a phenyl ring in the side chain ( Fig. 1 ) gave compounds that potently reversed the vasodilation produced by various K ATP channel openers but not that by other vasodilatory maneuvers; in addition, the inhibitory effect resided in one (i.e. the R-) enantiomer. It was concluded that the novel compounds acted as K ATP channel blockers. The results of their study may be interpreted in two ways. First, the compounds may have acted as "neutral antagonists" (i.e. by displacing the opener from SUR without directly affecting channel activity); channel closure would then be induced by the high intracellular ATP concentrations in the vascular smooth muscle cell. Alternatively, the compounds may have acted as "inverse agonists" (i.e. they displaced the opener, and, similar to the sulfonylureas, their binding induced channel block also in the absence of ATP). In order to decide between these alternatives, the enantiomers of one such compound, PNU-94750 ( Fig. 1) , were examined in electrophysiological experiments using recombinant K ATP channels. Since K ATP channel openers and blockers (such as sulfonylureas) differ in their allosteric coupling to MgATP binding (see above), we also investigated the effect of MgATP on the binding of the enantiomers in radioligand binding assays. The study showed that the enantiomers of PNU-94750 differed in their coupling to MgATP binding and that the R-enantiomer (PNU-96293) was negatively coupled and inhibited K ATP channels, whereas the S-enantiomer (PNU-96179) was positively coupled and was an opener.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection-SUR2B(Y1206S) was constructed from murine SUR2B (GenBank TM D86038 (18)) as described (26) . Human embryonic kidney (HEK) 293 cells were cultured in minimum essential medium containing glutamine and supplemented with 10% fetal bovine serum and 20 g/ml gentamycin (14) . Cells were transfected with the expression vector pcDNA3.1 (Invitrogen) containing the coding sequence of murine SUR2B, SUR2B(Y1206S), murine SUR2A (GenBank TM D86037 (18)), or rat SUR1 (GenBank TM X97279), and cell lines stably expressing these proteins were generated as described (14) . Cotransfection of SUR with murine Kir6.2 (D50581 (17)) was done transiently at a molar plasmid ratio of 1:1 using LipofectAMINE and Opti-MEM (Invitrogen) as described previously (14) . In cotransfections prepared for electrophysiological experiments, the pEGFP-C1 vector (CLONTECH, Palo Alto, CA), encoding for green fluorescent protein, was added for easy identification of transfected cells. 2-4 days after transfection, cells were used for binding studies and electrophysiological experiments.
Electrophysiological Experiments-The patch-clamp technique was used in the inside-out, the cell-attached, and the whole-cell configuration as described by Hamill et al. (27) . Patch pipettes were drawn from borosilicate glass capillaries (GC 150 or GC 150T; Harvard Apparatus, Edenbridge, UK) and heat-polished using a horizontal microelectrode puller (Zeitz, Augsburg, Germany). For experiments using inside-out patches, bath and pipette were filled with a high K ϩ -Ringer solution containing 142 mM KCl, 2.8 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 11 mM D-(ϩ)-glucose; 10 mM HEPES, titrated to pH 7.4 with NaOH at 22°C. After filling with buffer, pipettes had a resistance of 1-1.5 megaohms. After excision of the patch, the pipette was moved in front of a pipe with a high K ϩ -EGTA-Ringer solution containing 143 mM KCl, 0.85 mM MgCl 2 , 1 mM CaCl 2 , 5 mM EGTA, 11 mM D-(ϩ)-glucose, 10 mM HEPES, titrated to pH 7.2 with NaOH at 22°C. The PNU compounds and glibenclamide were dissolved in stock solutions as described under "Materials"; ATP was dissolved in buffer, and an appropriate amount of MgCl 2 was added to keep free Mg 2ϩ constant at 0.7 mM. Substances were applied to the patch via the pipe, and patches were clamped to Ϫ50 mV. For evaluation of the inhibition by PNU-96293, traces were individually corrected for run down.
For experiments in the cell-attached configuration, bath and pipette were filled with the high K ϩ -Ringer solution described above. After filling, the pipettes had a resistance of 1-1.5 megaohms. Patch experiments were performed at 37°C, and patches were clamped at Ϫ50 mV.
Experiments using the whole-cell configuration were performed as described by Russ et al. (28) . The bath solution was 142 mM NaCl, 2.8 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 11 mM D-(ϩ)-glucose, 10 mM HEPES, titrated to pH 7.4 with NaOH at 37°C. Patch pipettes were filled with 132 mM potassium glutamate, 10 mM NaCl, 2 mM MgCl 2 , 10 mM HEPES, 1 mM EGTA, 1 mM Na 2 ATP, titrated to pH 7.2 with NaOH, and had a resistance of 3-5 megaohms. Isolated cells were chosen. After establishing the whole cell configuration, cells were clamped to Ϫ60 mV, and every 12.5 s, the following square pulse protocol was applied. After 1 s at Ϫ60 mV, cells were clamped to the test potential of Ϫ110 mV for 0.5 s and then, after 1 s at Ϫ60 mV, to the next test potential of Ϫ90 mV, etc. (seven steps increasing by 20 mV from Ϫ110 to 10 mV). At the end of the protocol, capacitance and series resistance were measured, and the latter was compensated by 70%. To show the timedependent current at a specified voltage, data were averaged over the last 125 ms spent at that voltage during the cycle and spliced together to give a continuous curve.
Data were recorded with an EPC 9 amplifier (HEKA, Lambrecht, Germany) using the "Pulse" software (HEKA). Signals were filtered at 200 Hz using the four-pole Bessel filter of the EPC9 amplifier and sampled with 1 kHz.
Membrane Preparation, Equilibrium Competition Experiments, and Dissociation Kinetics-For cells stably expressing SUR alone, the antibiotic was withdrawn from the culture medium 1 week prior to membrane preparation. Membranes were prepared as described (14) . Protein concentration was determined according to Lowry et al. (29) using bovine serum albumin as the standard.
In equilibrium binding assays, membranes (final protein concentration 0.2-0.5 mg/ml) were added to the incubation buffer containing 139 mM NaCl, 5 For measurement of the dissociation kinetics, membranes were incubated with 2 nM [ 3 H]P1075 in the presence of 2.2 mM MgCl 2 and 1 mM Na 2 ATP at 37°C for 30 min. Dissociation was initiated by the addition of P1075 ϩ PNU-96293 (10 M each), and 300-l aliquots were withdrawn at different times for filtration as described above.
Equilibrium Binding Experiments in Cells-Experiments were conducted at 37°C with an incubation time of 30 min as described previously (14, 28) . Cells were suspended by rinsing with a HEPES-buffered physiological salt solution containing 139 mM NaCl, 5 mM KCl, 1.2 mM MgCl 2 , 1.25 mM CaCl 2 , 11 mM D-(ϩ)-glucose, 5 mM HEPES; gassed with 95% O 2 and 5% CO 2 ; and titrated to pH 7.4 with NaOH at 37°C. Binding experiments were started by the addition of cells (final concentration 1 ϫ 10 6 cells/ml, corresponding to 0.25 mg of protein/ml) to the buffer supplemented with ϳ2 nM [ 3 H]P1075 and the inhibitor of interest. After 30 min, incubation was stopped as described above, and aliquots were filtered over Whatman GF/C filters.
Data Analysis-Concentration dependencies were analyzed by fitting the logistic function
to the data. Here, A denotes the extent of the effect (amplitude); n (ϭ n H ) is the Hill coefficient, x is the concentration of the compound under study, and IC 50 the midpoint of the curve with px ϭ Ϫlog x and pIC 50 ϭ Ϫlog IC 50 . In binding experiments, the dependence of the midpoint of an inhibition curve (IC 50 value) on the concentration of the radioligand, L*, was calculated according to the equation by Cheng and Prusoff (30),
where K i is the inhibition constant and K L is the equilibrium dissociation constant of the radioligand, L*. In general, this correction did not exceed a factor of 1.5. In cases when a homologous competition experiment (e.g. L* Ϫ L) was conducted in the presence of a fixed concentration of a further ligand, C, that also competed with the radioligand, Equation 2 was expanded to read as follows,
where K C is the equilibrium dissociation constant of competitor C. The homologous competition curves (in the absence and presence of competitor) may be transformed according to Scatchard (31) ,
where B and F represent the bound and free concentration of the unlabeled ligand, L. B (in percent) is calculated from the radioactive ligand specifically bound, B*, as B ϭ 100 Ϫ B*.
Fits of the equations to the data were performed according to the method of least squares using the program SigmaPlot 6.1 (SPSS Science, Chicago, IL). Individual binding competition experiments were analyzed according to Equation 1. Errors in the parameters derived from the fit to a single curve were estimated using the univariate approximation (32) . Amplitudes and pK values are normally distributed (33); here, K values with the 95% confidence interval in parentheses are given. Propagation of errors was taken into account according to Bevington (34) .
Materials-PNU-96293 and PNU-96179 were synthesized according to Humphrey et al. (35) . [ 3 H]P1075 (specific activity 4.5 TBq (118 Ci) mmol Ϫ1 ) was purchased from Amersham Biosciences, and [ 3 H]glibenclamide (specific activity 1.85 TBq (50 Ci) mmol Ϫ1 ) was from PerkinElmer Life Sciences. The reagents and media used for cell culture and transfection were from Invitrogen (Karlsruhe, Germany). Na 2 ATP was from Roche Diagnostics, and glibenclamide was from Sigma. P1075 was a kind gift from Leo Pharmaceuticals (Ballerup, Denmark). K ATP channel modulators were dissolved in dimethyl sulfoxide/ethanol (1:1) and further diluted with the same solvent or with incubation buffer. In binding studies, the final solvent concentration in the assays was always below 0.3% (in electrophysiological experiments 0.1% or below).
RESULTS

PNU-96293 as an Inhibitor of Kir6.2/SUR2B Channels-
Khan and colleagues (25) have shown that PNU-96293, the R-enantiomer, reversed the vasorelaxation induced by other K ϩ channel openers. We therefore examined the effect of this compound on the recombinant K ATP channel in (nonvascular) smooth muscle, Kir6.2/SUR2B. After application of PNU-96293 (10, 30, and 100 M) to an inside-out patch in the presence of 1 mM MgATP, no current developed (data not shown). In agreement with Khan et al. (25) , this indicated that the compound was devoid of opener activity. When the channel was opened by reducing the ATP concentration to 3 M, the compound inhibited the channel concentration-dependently ( Fig. 2A) . At 100 M, the highest concentration tested, inhibition was ϳ50%. In comparison, glibenclamide, at the saturating concentration of 1 M, inhibited the current by 80%. The inhibition curve of the PNU enantiomer extrapolated to a maximum inhibition of 46% with an IC 50 value of 16 M (Fig. 2B, Table I ). In the absence of ATP, the current was inhibited maximally by 30% with an IC 50 value of 12 M ( Table I) .
The effect of PNU-96293 was also studied in the whole-cell configuration at 37°C (Fig. 3) . Dialysis of the cell with 1 mM MgATP generated a current that was inhibited by the PNU enantiomer in the nanomolar concentration range (IC 50 ϭ 78 nM) with a maximum inhibition of 74%; glibenclamide (1 M) induced almost total inhibition (Table I) . Analogous experiments using the Kir6.2/SUR2B(Y1206S) channel gave very similar results (Table I) , showing that the mutation did not alter the sensitivity of the channel to PNU-96293. Fig. 4A presents an original recording from an inside-out patch containing Kir6.2/SUR2B channels. The channel was kept closed by MgATP (1 mM); the addition of PNU-96179 (100 M) generated a current that was completely inhibited by glibenclamide (3 M) in a reversible manner. Further experiments showed that the current induced by PNU-96179 (100 M) was about 10 -20% of that produced by P1075 at the maximally effective concentration of 0.1 M; lower concentrations of the PNU compound showed smaller and inconsistent effects.
PNU-96179 as an Opener of the Kir6.2/SUR2B Channel-
The ability of PNU-96179 to open the Kir6.2/SUR2B channel was also examined in the whole-cell configuration; however, it proved difficult to keep the channel closed during prolonged dialysis of the cell with 3-10 mM MgATP. Experiments were therefore performed in the cell-attached configuration. Fig. 4B shows that PNU-96179 (100 M) activated the channels to 13% (mean 15.6 Ϯ 1.6; n ϭ 6) of the level produced by P1075 (0.1 M); at 10 M, the PNU compound was ineffective. Collectively, the data show that PNU-96179 is an opener of the Kir6.2/ SUR2B channel, albeit with low potency and efficacy. The opening properties were not investigated further, since channel opening is an effect expected for a cyanoguanidine. (Table II) . Hence, stereoselectivity of binding, measured as the eudismic (ϭ K i ) ratio, was weak (3.5). Similar experiments were performed also at an ATP concentration of 3 M (i.e. the lowest concentration at which high affinity binding of the radioligand (which requires MgATP) is detected) (14, 15) . Under these conditions, the inhibition curve for PNU-96179 was shifted to the right by a factor of 2.7 and that of PNU-96293 to the left by a factor of 10, giving now a eudismic ratio of 100. Hence, increasing ATP increased the potency of PNU-96179 and strongly decreased that of PNU-96293, indicating positive allosteric coupling between PNU-96179 and MgATP binding, whereas for PNU-96293, the coupling to MgATP was negative.
In order to facilitate comparison with the electrophysiologi- A, original recording. The cell was clamped at Ϫ60 mV, and voltage was stepped from Ϫ110 to 10 mV in 20-mV steps as described under "Experimental Procedures." During dialysis of the cell with MgATP (1 mM) at 37°C, a current developed that was inhibited by PNU-96293 in a concentration-dependent manner. After washout, glibenclamide (1 M) produced total inhibition. B, concentration-dependent inhibition at Ϫ60 mV. The fit of Equation 1 with Hill coefficient 1 to the data (mean values from the number of patches given in parentheses) gave the parameters listed in Table I .
Stereoselective Gating of K ATP Channels
cal experiments, binding experiments were also performed in intact HEK cells cotransfected with Kir6.2 plus SUR2B. Under these conditions, the enantiomers inhibited binding of the radioligand with K i values of 3.6 and 0.2 M, respectively. Comparison with the K i values determined in membranes with SUR2B alone at 1 mM ATP showed that coexpression with Kir6.2 and/or the whole cell environment increased the K i value of PNU-96179 slightly by a factor of 1.6 Ϯ 0.2 but decreased that of PNU-96293 by a factor of 3.4 Ϯ 0.4 (Table II) . The gain in potency of PNU-96293 obtained by these changes resembled that seen earlier with glibenclamide (26) .
Since the PNU compounds and P1075 are structurally related ( Fig. 1) , we examined whether these ligands competed for the same site of SUR2B. To this end, homologous [
3 H]P1075-P1075 competition experiments were performed in the absence and presence of PNU-96179 (10 M) or PNU-96293 (3 M). The idea behind this was that the presence of the PNU compounds, if they competed with P1075 for the same binding site at SUR2B, should shift the P1075 binding curve to the right as predicted by Equation 3. Fig. 6 shows the inhibition curves in the Scatchard representation (see "Experimental Procedures"). Both PNU compounds reduced the slope but left the abscissa intercept unchanged. The observed reductions in P1075 affinity produced by 10 M PNU-96179 (3.3ϫ) and 3 M PNU-96293 (4.4ϫ) are in quantitative agreement with those calculated assuming competition with P1075 (Equation 3) and using the K i values determined in Fig. 5 .
If the PNU enantiomers bind to the same site as P1075, they should not affect the dissociation kinetics of P1075 from SUR2B. In control experiments, the addition of unlabeled P1075 in large excess (10 M) to the SUR2B- [ 3 H]P1075 complex induced dissociation of the complex with a half-time of 11 min. PNU-96293 (10 M) in the presence of P1075 (10 M) did not alter the half-time of dissociation (data not shown).
Interaction of PNU Enantiomers with SUR2B: [ 3 H]Glibenclamide Binding
Experiments-Glibenclamide and opener binding sites at SUR2B are linked by strict negative allosteric coupling (14, 24) ; in addition, glibenclamide binding and MgATP binding are negatively allosterically coupled (36) . The coupling between binding of the PNU enantiomers and ATP was therefore examined also using [ 3 H]glibenclamide as the radioligand. Since high affinity glibenclamide binding is increased in the absence of MgATP, this offers the advantage of studying the coupling over a wider range of MgATP concentrations. However, the affinity of SUR2B for glibenclamide (K D ϭ 22 nM (36)) is too low to obtain a good signal; use was therefore made of the SUR2B(Y1206S) mutant, which has a 5.5 times higher affinity for glibenclamide (26) . We have shown previously that neither opener binding nor the allosteric coupling between the binding of ATP, opener, and glibenclamide are perturbed by this mutation (26, 36 (Fig. 2B, Table I ) (i.e. with parameters similar to those found with the Kir6.2/SUR2B channel). In the whole cell mode, a large scatter of the data was noted. Data were therefore divided into two groups according to their glibenclamide sensitivity. Analyzing the group with high sensitivity to glibenclamide (at 1 M glibenclamide: 79 Ϯ 6% block; n ϭ 3), the inhibition curve extrapolated to 68 Ϯ 4% block at saturation with an IC 50 value of 14 (8, 23) nM (Table I ). The inhibition curve of the cells with poor sensitivity to glibenclamide (block at 1 M: 47 Ϯ 15%; n ϭ 4) gave a maximum extent of inhibition of 39 Ϯ 11% and an IC 50 value 0.5 (0.2, 1.3) M. This showed that the channels with poor sensitivity to glibenclamide were also quite insensitive to PNU-96293. In (Table II) . These results were qualitatively similar to the observations made with SUR2B; however, the ATP-induced shifts were smaller (Table II) .
In inside-out patches in the absence of ATP, PNU-96293 (100 M) inhibited the Kir6.2/SUR1 current by 40 Ϯ 5% (n ϭ 13); similar inhibition was obtained with tolbutamide at 100 M (Table I) . In binding experiments, PNU-96179 proved very weak in inhibiting [ 3 H]glibenclamide binding to SUR1: at 1 mM, inhibition amounted to ϳ55% independent of the presence of MgATP. Extrapolating the curves to 100% inhibition at saturation gave IC 50 values of ϳ550 M (i.e. an ϳ100-fold lower potency than found for the SUR2 subtypes) (Table II) . PNU-96293 exhibited a behavior qualitatively similar to that observed at SUR2B(Y1206S) ( 
DISCUSSION
Here we report that the enantiomers of a racemic compound derived from the K ATP channel opening cyanoguanidines interact specifically with the channel, the R-enantiomer (PNU-96293) inducing channel inhibition and the S-enantiomer (PNU-96179) opening.
Inhibition of Recombinant K ATP Channels by PNU-96293-In whole cell experiments and in the presence of ϳ1 mM MgATP, PNU-96293 inhibited the Kir6.2/SUR2 channels with IC 50 values in the low nanomolar range and a slight selectivity for the Kir6.2/SUR2A channel. This is a potency similar to that of glibenclamide under the same conditions (26) . The efficacy of PNU-96293, however, was lower than that of glibenclamide at both Kir6.2/SUR2 channels (Table I ). This may be related to differences in the negative allosteric coupling to MgATP binding at SUR. Here we have shown that MgATP decreases the affinity of PNU-96293 for SUR2B; in the case of glibenclamide binding, however, the number of binding sites is reduced (23, 26) .
Another point deserves comment. For the Kir6.2/SUR2B channel, the binding and the electrophysiological experiments were performed under similar conditions (whole cells, high MgATP, 37°C); however, the channel inhibition curve (IC 50 ϭ 78 nM) was shifted leftward from the binding curve (K i ϭ K D ϭ 200 nM) by a factor of ϳ3. A leftward shift of roughly this magnitude is expected if the channel has four equal and independent sites for the ligand and if occupation of a single site is sufficient for channel inhibition (37) . Alternatively, if binding of four molecules is required for channel block, the shift is by the same factor ((2 1 ⁄4 Ϫ 1) Ϫ1 ϭ 5.3 (28)) but in the opposite direction.
Using the inside-out configuration, the potency and efficacy of PNU-96293 in blocking the Kir6.2/SUR2 channels were reduced. The loss in potency was dramatic (IC 50 values in the 20 M range); it was also unexpected for two reasons. First, the contrary is observed with sulfonylureas (e.g. glibenclamide) and analogs (e.g. repaglinide); in these cases, the sensitivity for channel block is increased in the inside-out patch (glibenclamide (26, 38) and repaglinide (39)). Second, the IC 50 values for channel inhibition are 190 -250 times higher than the K i values of the respective binding curves. Despite some differences in the experimental conditions (binding experiments were done at 37°C and to SUR alone), these observations suggest that the transduction of PNU binding into to channel inhibition is more complex than in the case of the sulfonylureas. One may speculate that the more physiological environment of the (dialyzed) whole cell offers a component (e.g. another protein, a metabolic product) not present in the inside-out patch. Further work is needed to resolve this question. The other point is the lower efficacy of block observed in the insideout configuration. This is less surprising, since it has generally been observed with all K ATP channel inhibitors acting via SUR (e.g. see Refs. 38, 40, and 41). The reason for this behavior remains unknown.
Binding Sites of the Enantiomers-Information on the binding site(s) of SUR for the PNU enantiomers was obtained from the binding experiments. First we recall that SUR accommodates the binding sites for the openers, the sulfonylureas, and nucleotides, and that these sites are linked by allosteric interactions ( Fig. 8A ; see also the Introduction). The partial inhibition of or even the increase in [ 3 H]glibenclamide binding to SUR2B(Y1206S) and SUR1 excluded the possibility that the enantiomers bound to the glibenclamide site of SUR. Instead, these results showed that ternary complexes of SUR with glibenclamide and a PNU enantiomer existed at equilibrium and that the site(s) of the PNU enantiomers and the glibenclamide site were linked by allosteric interactions. Similarly, the modulation of PNU binding by MgATP showed allosteric linkage between the PNU site(s) and nucleotide binding to the nucleotide binding folds of SUR. The equilibrium binding experiments with [ 3 H]P1075 in Fig. 6 and the kinetic experiments, however, were in quantitative agreement with a model in which the PNU enantiomers and P1075 competed for the same binding site of SUR2B. In view of the structural similarity between these three ligands ( Fig. 1) , competition for the same binding site seems plausible; however, more direct biochemical evidence (e.g. by photoaffinity labeling) is desirable. A first consequence of the competitive mechanism was that the K i values determined in [
3 H]P1075 inhibition assays (Table II tion in the affinity of PNU-96293 binding to SUR2B(Y1206S) (rightward shift ϳ100-fold), whereas for glibenclamide the number of binding sites was reduced (23, 36) . Regarding binding to SUR1, MgATP induced a rightward shift in both cases, and the shift for PNU (22, (Fig. 7B ) and to SUR1 (Table II) . Including MgATP, one is faced with a system of three binding sites, linked by negative allosteric interactions of differing strength (Fig. 8B) (Fig. 8B) . In the absence of MgATP (Fig. 8C) Table II. upon increasing ATP depended on the SUR subtype (SUR2B Ͼ SUR2A; SUR2B(Y1206S) Ͼ SUR1; Table II); this suggested differences in the strength of the negative allosteric coupling between PNU-96293 and MgATP binding with the SUR subtype. Variable MgATP-induced rightward shifts were observed previously for the binding of glibenclamide and of the sulfonylthiourea, HMR 1883, to SUR subtypes; in this case, the maximum shift (measured as the ratio of the K i values) was ϳ8 for glibenclamide binding to SUR1 (38) . In addition, the glinide, AZ-DF265 (42), also displayed a rightward shift of 2.8-fold in its interaction with SUR2B. 2 Collectively, these data show that compounds of different chemical structures, which inhibit K ATP channels by binding to the SUR subunit, are negatively allosterically coupled to MgATP binding to SUR.
Allosteric Coupling of PNU-96179 and MgATP BindingIncreased MgATP induced a leftward shift in binding of the S-enantiomer to SUR2, indicating positive allosteric coupling between the respective binding sites. With [ 3 H]P1075 binding to SUR2B and an increase in MgATP from 0.003 to 1 mM, the leftward shift measured for PNU-96179 was ϳ3-fold (Table II) . This is in the range typical for openers; for P1075 it was 1.7-fold (14) , and for the benzopyran 217-774 (43) it was 3.8-fold. 2 Much higher shifts were found with [
3 H]glibenclamide as the radioligand, probably because one can start from MgATP ϭ 0. In this case, and using the mutant SUR2B(Y1206S), the shift for PNU-96179 amounted to a ratio of 33; for typical openers, it ranged from 100 to 300 (44) . These data show that openers of different chemical structures are positively allosterically coupled to MgATP binding. In view of the fact that openers increase the ATPase activity of SUR (21), this is not surprising.
Eudismic Ratio and Affinity of the PNU Enantiomers-At 1 mM MgATP, the PNU enantiomers bound to the different SUR subtypes in the low (SUR2) or high (SUR1) micromolar range (i.e. binding was relatively weak). The eudismic (ϭ K D ) ratio of the enantiomers was also weak, ranging from ϳ1 (SUR2B-(Y1206S)) to 17 (SUR1). Hence, the largest ratio was found for the SUR with the weakest affinity for the PNU compounds (i.e. SUR1). This was also true for the K i values at low or 0 MgATP (Table I ). These observations are not in accordance with Pfeiffer's rule, which states that the weaker the racemate, the smaller the potency difference between the enantiomers (45) . One also notes that for all SUR subtypes, PNU-96293 was more potent than PNU-96179, which agrees with the electrophysiological experiments.
Significance of Results-The major result of this study was that the R-enantiomer of the racemic cyanoguanidine, PNU-94750, exhibited the higher potency (25) , was negatively coupled to MgATP binding, and inhibited K ATP channels; for the S-enantiomer, the converse was true in all points. Stereoselective gating of K ATP channels has been observed before, both for openers (e.g. for cromakalim (e.g. see Ref. 46 ) and for cyanoguanidines like pinacidil (47) ) and for blockers (e.g. the benzoic acid sulfonylurea analogue AZ-DF 265 (42, 48) ). In all of these cases, the distomer affected the channel in the same way as the eutomer but with reduced potency. Within the cyanoguanidine class, the PNU eutomer exhibited the R configuration as in the case of pinacidil. However, the S-enantiomer can also be the eutomer, indicating that SUR has considerable flexibility in accommodating the ligand (47) (for a review, see Ref. 4) . More importantly, the PNU eutomer was a K ATP channel blocker, and the two enantiomers had opposite molecular effects.
These observations are reminiscent of some dihydropyridines where, depending on membrane voltage and channel kinetics, one enantiomer can open and the other close the L-type Ca 2ϩ channel (49, 50) . These opposite actions are apparently mediated by binding to the same binding site of the channel (51) . The enantiomers shift the channel inactivation curve by different degrees to more negative potential, which, in a certain voltage window, results in an increase or decrease in the number of activable channels (50) . Regarding the PNU enantiomers, the available evidence suggests that they also bind to the same binding site of their receptor (SUR); however, they show opposite effects in their allosteric coupling to ATP binding (and possibly ATPase activity) and in their modulation of K ATP channel activity. Within the framework of the biochemical mechanism of K ATP channel openers (21, 52) and blockers (13) , one may hypothesize that it is not the binding of a ligand to the opener site of SUR per se but the modulation by this ligand of ATP binding and ATPase activity of SUR that determines whether the compound acts as an opener or a blocker of the channel.
